Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2020)
22 slides from Somnomed's shareholder meeting presentation, Nov 26, 2020
Slide 1: Chairman's AGM address by Mr Guy Russo
The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge St Sydney NSW 2000 Chairman’s AGM address by Mr Guy Russo 2020 Annual General Meeting ‐ 26 November, 2020 Dear Shareholders It is an honour to address you today as your new Chairman. I have said this to the man
Slide 2: Chairman's address (continued)
Neil and his team work tirelessly with various authorities to promote stronger clinical guidelines, as well as investing in and supporting clinical research, which validates the treatment option. We also work with insurance companies to treat their members with a SomnoDent® so that they, too, can be
Slide 3: Managing Director's address by Mr Neil Verdal-Austin
Managing Director’s address by Mr Neil Verdal‐Austin 2020 Annual General Meeting 26 November, 2020 It is indeed an honour to address you today and provide you with an update on the business. It is now two years ago that I was appointed as your CEO and we began a new journey for SomnoMed Limited. Thr
Slide 4: Goals achieved during the year
Despite that, we have achieved many of the goals I had set the organization for the year: Strong growth in the US where we have restructured and invested in operational service excellence and a new digital product offering with a new Sales and Marketing team; New sales leader appointed and a med
Slide 5: Thank you for your trust and support
Thank you all for your trust and support in our company, in me as your Managing Director and CEO and to the executive team who have helped me to achieve the results that we have seen during the past 12 months. We look forward to continued growth in the current financial year and beyond. Thank you fo
Slide 6: AGM Presentation
AGM Presentation November 2020
Slide 7: Agenda
Agenda FY20 Performance & Key Takeaways Future Horizons FY21 Outlook 6
Slide 8: FY20 Performance & Key Takeaways
FY20 Performance & Key Takeaways 7
Slide 9: FY20 at a glance
FY20 at a glance Revenue (A$m) Summary of performance $70 FY19 FY20 SomnoMed performed strongly up to 31 March 2020 before -3% YoY experiencing significant headwinds as a result of COVID-19. $60 $50 Despite these challenges, we have achieved many of the goals +15% YoY -22% YoY set for the business t
Slide 10: History of continued innovation around the patient
History of continued innovation around the patient 2018 2020 Digital manufacturing New Board platform and MD 2014 2010 MASPAP study Manufacturing (Philips & ISO 13485 Cistulli) 2019 SomnoDent® 2018 2008 Avant France CE mark 2013/2014 2014 2017 reimbursement Europe SomnoDent® Belgium change expansion
Slide 11: Positioned for growth
Positioned for growth Technology driven Investment in the technology pathway to unlock true COAT™ potential Best in class service and technical support Growing and extensive sales and distribution Treatment footprint in both dental and medical channels focused Design and innovation driving patient c
Slide 12: Highly supportive Board
Highly supportive Board New Board members with the diversity of skill set, perspective, experience, and background to drive our journey towards being a more technology enabled sleep apnea solutions business Guy Russo Amrita Hilton Michael Karen Chairman Blickstead Brett Gordon Borg • Highly accompli
Slide 13: Experienced management team
Experienced management team Neil Verdal-Austin CEO • Joined SomnoMed in July 2019 • Joined SomnoMed in April 2019 • Strong track record of executing sales & marketing • Extensive experience in managing all aspects of managing strategies in APAC, Europe and Australia finance, IT, supply chains, globa
Slide 14: Future Horizons
Future Horizons 13
Slide 15: Our future horizons
Our future horizons + + Advancing treatment and Positioning the patient’s Technology building the core alternative driven Category leadership in a multi-billion dollar opportunity 14
Slide 16: Advancing treatment and building the core
Advancing treatment and building the core Service Support & Excellence Global Sales & Marketing Footprint Industry best practises with service and Continued investment in global medical customer support field sales teams Technological, real-time innovations for Marketing initiatives driving acceptan
Slide 17: Positioning the patient's alternative
Positioning the patient’s alternative Show Sleep Physicians how Intensified efforts to position COAT™ and CPAP can be Effectiveness COAT™ as an effective alternative equally effective over a Equation to CPAP drives increases in patient’s full night of sleep COAT™ share of OSA therapy Focus is on sup
Slide 18: Proven ability to build market share
Proven ability to build market share Estimated COAT™ penetration in SomnoMed global markets 100% 90% 80% 70% 60% 50% 40% 30% 52% 20% 40% 25% 30% 10% 15% 18% 7% 8% 12% 0% 4% 5% 5% Italy Spain CH Germany USA France Australia Belgium Finland Norway NL Sweden Netherlands Sweden Estimated 40% share of to
Slide 19: Technology driven
Technology driven One integrated and automated technology platform Realtime dental clinical decision & acceptance App-Nea Portal Bridge between medical & Data dental Devices Connectivity, big data & personalised medicine Clinical Screening & diagnosis evidence Analytics optimisation Reimbursement po
Slide 20: Investing to achieve category leadership
Investing to achieve category leadership Financial framework for growth and profitability Accelerated Balanced Mature growth growth growth invest EBITDA Top & Priority Top line bottom line Bottom line into future horizons Annual revenue >20% 15-20% 10-15% growth to accelerate growth EBITDA1 Maintain
Slide 21: FY21 Outlook
FY21 Outlook 20
Slide 22: FY21 Outlook
FY21 Outlook FY21 Guidance Key Considerations Key Strategic Objectives No guidance is currently Stabilise and respond to Treatment Focused provided for FY21 due to the changing market conditions uncertainties created by Medical sales and marketing COVID-19 Drive growth opportunities investment and i